Fund shareholders of Halozyme Therapeutics Inc
ISIN US40637H1095 · United States · LEI 529900242I3SV9AGM753
- Fund shareholders
- 513
- Of which ETFs
- 142 371 other funds
- Value held
- ≈ 3.8B $ 3.7B $ · 1.6M € · 424.1M SEK
- Share of capital
- 42.7 % of 113.5M shares on Jul 31, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Mid-Cap 1.5x Strategy Fund Rydex Variable Trust | 99 | 7.7K $ | 0.19 % | 0.00 % | as of Jun 30, 2026 ↗ |
| SA Franklin Tactical Opportunities Portfolio SUNAMERICA SERIES TRUST | 80 | 6.6K $ | 0.01 % | 0.00 % | as of Jul 31, 2026 ↗ |
| VIP Hedged Equity Portfolio Variable Insurance Products Fund VI | 50 | 3.9K $ | 0.02 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Kennedy Capital Small Cap Growth Fund INVESTMENT MANAGERS SERIES TRUST II | 48 | 3.8K $ | 0.54 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Columbia Research Enhanced Mid Cap ETF Columbia ETF Trust I | 28 | 2.2K $ | 0.06 % | 0.00 % | as of Jun 30, 2026 ↗ |
| MUTUAFONDO SALUD, FI MUTUACTIVOS, S.A., S.G.I.I.C. | 560.4K € | 3.14 % | as of Dec 31, 2025 ↗ | ||
| GESTION BOUTIQUE VI, FI GESTION BOUTIQUE VI / FUNDAMENTAL APPROACH ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 332.3K € | 5.29 % | as of Dec 31, 2025 ↗ | ||
| GVC GAESCO ZEBRA US SMALL CAPS LOW POPULARITY, FI GVC GAESCO GESTIÓN, SGIIC, S.A. | 222K € | 1.70 % | as of Dec 31, 2025 ↗ | ||
| GESIURIS HEALTHCARE & INNOVATION FI GESIURIS ASSET MANAGEMENT, SGIIC, S.A. | 217.7K € | 1.22 % | as of Dec 31, 2025 ↗ | ||
| GESTION BOUTIQUE VI, FI GESTION BOUTIQUE VI / KALDI ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 143.2K € | 1.47 % | as of Dec 31, 2025 ↗ | ||
| GESTION BOUTIQUE IV, FI GESTION BOUTIQUE IV/ALCLAM US EQUITIES ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 85.9K € | 1.29 % | as of Dec 31, 2025 ↗ | ||
| COMPROMISO MEDIOLANUM, FI MEDIOLANUM GESTION, S.G.I.I.C., S.A. | 57.5K € | 0.14 % | as of Dec 31, 2025 ↗ | ||
| GESTION BOUTIQUE VII, FI GESTION BOUTIQUE VII / TOP QUALITY OPPORTUNITIES ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 26.9K € | 2.12 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| GESTION BOUTIQUE VI, FI GESTION BOUTIQUE VI / FUNDAMENTAL APPROACH ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 5.29 % | as of Dec 31, 2025 ↗ |
| The Future Fund Long/Short ETF NORTHERN LIGHTS FUND TRUST II | 3.53 % | as of May 31, 2026 ↗ |
| Leadershares Alphafactor Tactical Focused ETF Two Roads Shared Trust | 3.43 % | as of Jul 31, 2026 ↗ |
| Congress Mid Cap Growth Fund Professionally Managed Portfolios | 3.31 % | as of Jul 31, 2026 ↗ |
| FundX Future Fund Opportunities ETF FundX Investment Trust | 3.20 % | as of Jun 30, 2026 ↗ |
| M3Sixty Income and Opportunity Fund 360 Funds | 3.18 % | as of May 31, 2026 ↗ |
| MUTUAFONDO SALUD, FI MUTUACTIVOS, S.A., S.G.I.I.C. | 3.14 % | as of Dec 31, 2025 ↗ |
| First Trust NYSE Arca Biotechnology Index Fund First Trust Exchange-Traded Fund | 3.11 % | as of Jun 30, 2026 ↗ |
| Invesco Biotechnology & Genome ETF Invesco Exchange-Traded Fund Trust | 2.98 % | as of Jul 31, 2026 ↗ |
| Congress SMid Growth ETF Professionally Managed Portfolios | 2.87 % | as of Jul 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 499 | -7 | 47,792,186 | -0.4 % |
| 2026Q2 | 506 | +14 | 47,994,208 | +6.4 % |
| 2026Q1 | 492 | -28 | 45,112,481 | -3.9 % |
| 2025Q4 | 520 | +9 | 46,966,645 | -5.9 % |
| 2025Q3 | 511 | +13 | 49,908,576 | -13.4 % |
| 2025Q2 | 498 | +30 | 57,626,404 | -1.4 % |
| 2025Q1 | 468 | -30 | 58,425,945 | -3.2 % |
| 2024Q4 | 498 | +7 | 60,334,863 | +0.8 % |
| 2024Q3 | 491 | +18 | 59,870,540 | -1.9 % |
| 2024Q2 | 473 | -1 | 61,022,777 | +0.8 % |
| 2024Q1 | 474 | +9 | 60,558,972 | -2.3 % |
| 2023Q4 | 465 | 62,016,133 |
Institutional managers
626 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| BlackRock, Inc. | 13,265,053 | 857.3M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 4,937,854 | 319.1M $ | as of Mar 31, 2026 |
| Invesco Ltd. | 4,012,494 | 259.3M $ | as of Mar 31, 2026 |
| BANK OF AMERICA CORP /DE/ | 2,913,109 | 188.3M $ | as of Mar 31, 2026 |
| Boston Partners | 2,683,683 | 173.4M $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 2,562,309 | 165.6M $ | as of Mar 31, 2026 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 2,525,975 | 163.3M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 2,505,786 | 162M $ | as of Mar 31, 2026 |
| SNYDER CAPITAL MANAGEMENT L P | 2,323,077 | 150.1M $ | as of Mar 31, 2026 |
| DIMENSIONAL FUND ADVISORS LP | 2,079,827 | 134.4M $ | as of Mar 31, 2026 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1,918,149 | 124M $ | as of Mar 31, 2026 |
| D. E. Shaw & Co., Inc. | 1,868,708 | 120.8M $ | as of Mar 31, 2026 |
| ALLIANCEBERNSTEIN L.P. | 1,736,501 | 116.9M $ | as of Mar 31, 2026 |
| ROYAL LONDON ASSET MANAGEMENT LTD | 1,610,553 | 104.1M $ | as of Mar 31, 2026 |
| JUPITER ASSET MANAGEMENT LTD | 1,608,256 | 103.9M $ | as of Mar 31, 2026 |
| TWO SIGMA INVESTMENTS, LP | 1,584,961 | 102.4M $ | as of Mar 31, 2026 |
| WELLS FARGO & COMPANY/MN | 1,535,737 | 99.3M $ | as of Mar 31, 2026 |
| FIRST TRUST ADVISORS LP | 1,482,340 | 95.8M $ | as of Mar 31, 2026 |
| FULLER & THALER ASSET MANAGEMENT, INC. | 1,465,283 | 94.7M $ | as of Mar 31, 2026 |
| GW&K Investment Management, LLC | 1,393,875 | 90.1K $ | as of Mar 31, 2026 |
| LSV ASSET MANAGEMENT | 1,371,558 | 88.6K $ | as of Mar 31, 2026 |
| MIZUHO MARKETS AMERICAS LLC | 1,323,544 | 85.5M $ | as of Mar 31, 2026 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,289,533 | 83.3M $ | as of Mar 31, 2026 |
| CONGRESS ASSET MANAGEMENT CO | 1,280,592 | 82.8M $ | as of Mar 31, 2026 |
| JANUS HENDERSON GROUP PLC | 1,233,658 | 79.7M $ | as of Mar 31, 2026 |
Funds holding the debt of Halozyme Therapeutics Inc
65 funds declare 94 bond lines of this company. The table shows the 25 largest holdings. The amount is the one the fund files. It is not a share of the debt, because no regulator publishes the amount outstanding in open access.
Cite this page
Titelia. "Fund shareholders of Halozyme Therapeutics Inc". https://titelia.com/en/stocks/halozyme-therapeutics-inc-US40637H1095